CN110917062A - Nano emulsion for promoting hair growth and preparation method thereof - Google Patents
Nano emulsion for promoting hair growth and preparation method thereof Download PDFInfo
- Publication number
- CN110917062A CN110917062A CN201911315867.5A CN201911315867A CN110917062A CN 110917062 A CN110917062 A CN 110917062A CN 201911315867 A CN201911315867 A CN 201911315867A CN 110917062 A CN110917062 A CN 110917062A
- Authority
- CN
- China
- Prior art keywords
- emulsion
- hair growth
- nano
- baicalin
- glutathione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003779 hair growth Effects 0.000 title claims abstract description 41
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 31
- 230000001737 promoting effect Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 66
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 46
- SKQIRRPTHXKMFU-UHFFFAOYSA-N N1(CCCC1)C1=[N+](C(=CC(=N1)N)N)[O-] Chemical compound N1(CCCC1)C1=[N+](C(=CC(=N1)N)N)[O-] SKQIRRPTHXKMFU-UHFFFAOYSA-N 0.000 claims abstract description 29
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 29
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 29
- 229960003321 baicalin Drugs 0.000 claims abstract description 29
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000002114 nanocomposite Substances 0.000 claims abstract description 29
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 25
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 25
- 239000004359 castor oil Substances 0.000 claims abstract description 25
- 235000019438 castor oil Nutrition 0.000 claims abstract description 25
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims abstract description 25
- 229940093471 ethyl oleate Drugs 0.000 claims abstract description 25
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 25
- 229940067606 lecithin Drugs 0.000 claims abstract description 25
- 235000010445 lecithin Nutrition 0.000 claims abstract description 25
- 239000000787 lecithin Substances 0.000 claims abstract description 25
- -1 polyoxyethylene Polymers 0.000 claims abstract description 25
- 108010024636 Glutathione Proteins 0.000 claims abstract description 23
- 229960003180 glutathione Drugs 0.000 claims abstract description 23
- 229960004756 ethanol Drugs 0.000 claims abstract description 22
- 239000000839 emulsion Substances 0.000 claims abstract description 14
- 229960001777 castor oil Drugs 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000008367 deionised water Substances 0.000 claims description 17
- 229910021641 deionized water Inorganic materials 0.000 claims description 17
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 229960005323 phenoxyethanol Drugs 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- RFHCUXJIPZTRBX-GEMLJDPKSA-N CCO.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O Chemical compound CCO.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RFHCUXJIPZTRBX-GEMLJDPKSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003205 fragrance Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 150000001875 compounds Chemical class 0.000 abstract description 16
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 239000003630 growth substance Substances 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 14
- 201000004384 Alopecia Diseases 0.000 description 12
- 210000003780 hair follicle Anatomy 0.000 description 11
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 231100000360 alopecia Toxicity 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000003359 percent control normalization Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 201000002996 androgenic alopecia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- 239000003936 androgen receptor antagonist Substances 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 210000000642 hair follicle dermal papilla cell Anatomy 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Abstract
The invention discloses a nano emulsion for promoting hair growth and a preparation method thereof, wherein the nano emulsion comprises a hair growth promoting compound consisting of pyrrolidinyl diaminopyrimidine oxide and baicalin, and a nano compound consisting of polyoxyethylene castor oil, lecithin, ethyl oleate, glutathione and ethanol and having a particle size of 10-133 m; the mass ratio of the pyrrolidinyl diaminopyrimidine oxide to the baicalin is 5: 2. The nanometer compound for promoting hair growth provided by the invention is an effective hair growth substance composed of pyrrolidinyl diaminopyrimidine oxide and baicalin, can effectively promote hair growth, and is low in irritation, good in stability and stronger in effect after being prepared into nanometer emulsion; the preparation method is simple in preparation process, can prepare the nano-composite with the hair growth effect at low temperature and normal pressure, does not contain any toxic reagent, is green and efficient, has a short period and high yield, and is easy to popularize and produce on a large scale.
Description
Technical Field
The invention belongs to the technical field of cosmetic preparation, relates to a compound for promoting hair growth, and particularly relates to a nanoemulsion for promoting hair growth and a preparation method thereof.
Background
The alopecia is mainly androgenetic alopecia which accounts for about 86% of the alopecia population, is mainly caused by genetic factors and is also related to combined effects of 5 α -reductase with overhigh activity, increased expression of male hormone receptors, blood circulation obstruction around hair follicles, bacterial infection, skin inflammation and the like at present, the alopecia can be caused at any age, currently, available treatment methods for the alopecia are extremely limited, western medicines mainly comprise chemical compositions represented by minoxidil, finasteride, JAK inhibitors and the like, but the western medicines are not suitable for the alopecia population due to narrow adaptation diseases, obvious side effects and high price, the traditional Chinese medicines have small toxic and side effects, low price and great advantages and can be easily obtained, the traditional Chinese medicines are often used for the alopecia population due to poor content and stability of extracts of traditional Chinese medicines produced by taking plant extracts as raw materials, the effective components of the hair growing substances and the high stability of the traditional Chinese medicines are not easy to be used, the effective tincture is not easy to obtain great significance, and the effective tincture is not easy to ensure.
Therefore, the development of a product capable of treating androgenic alopecia is imminent.
Disclosure of Invention
The present invention aims to overcome the defects of the prior art and provide a nano emulsion for promoting hair growth and a preparation method thereof. The nanoemulsion provided by the invention can effectively break through the stratum corneum of the skin, and penetrate into hair follicles, so that the active substance components are absorbed through the skin, and the hair growth is effectively promoted.
In order to achieve the purpose, the invention adopts the technical scheme that: a compound for promoting hair growth comprises pyrrolidinyl diaminopyrimidine oxide and baicalin; the mass ratio of the pyrrolidinyl diaminopyrimidine oxide to the baicalin is 5: 2.
The pyrrolidinyl diaminopyrimidine oxide is a hair growth promoter, is similar to minoxidil in structure, has different action principles, does not belong to the class of medicines, is a raw material approved by cosmetics, is safe and free of toxic and side effects, influences potassium ion channels through antagonism to a potassium ion channel switch inhibitor, promotes proliferation of epidermal hair papilla cells, relaxes blood vessels around hair follicles, improves scalp microcirculation, provides nutrition necessary for hair growth, promotes conversion of hair from a resting period to a growing period, and maintains a longer growing period.
Baicalin is an androgen receptor antagonist, has the effects of promoting the induction of the hair growth phase and increasing the activity of hair follicle dermal papilla cells, stimulating the secretion of vascular endothelial growth factors by the hair follicle dermal papilla cells to promote the growth of hair follicles, and activating a classical Wnt/β -catenin signaling pathway to increase the proliferation and differentiation capacities of fibroblasts and osteoblasts.
The invention preferably selects the combination of the pyrrolidinyl diaminopyrimidine oxide and the baicalin, and the mass ratio of the pyrrolidinyl diaminopyrimidine oxide to the baicalin is 5:2, so that the composition has the effect of synergistically promoting hair growth.
The complexes are useful for preparing products for promoting hair growth.
Also claimed is a hair growth lotion comprising the hair growth promoting complex.
Preferably, the hair growth promoting emulsion is a hair growth promoting nanoemulsion comprising the hair growth promoting compound and a nanocomposite.
In a preferred embodiment of the present invention, the content of the hair growth promoting composition in the nanoemulsion is 7% by mass.
As a preferred embodiment of the invention, the nano-composite consists of lecithin, polyoxyethylene castor oil, ethyl oleate, glutathione and ethanol, and the particle size of the nano-composite is 10-133 nm.
The lecithin, the polyoxyethylene castor oil, the ethyl oleate, the glutathione and the ethanol form a nano compound with water, namely a thermodynamically stable dispersion system formed by mixing a surfactant, an auxiliary surfactant, oil and water in a proper proportion. It has the incomparable characteristics of other drug carriers: 1) the appearance is transparent or semitransparent, the particles are uniform and the particle size is small; 2) the system is thermodynamically stable; 3) the preparation is simple, can be formed by only needing proper proportion of each component without much external force acting, and is independent of the adding sequence of the oil-water phase; 4) can be uniformly mixed with oil phase and water phase within a certain range; 5) increasing the solubility of poorly soluble drugs; 6) protecting easily oxidized and unstable medicaments; 7) reduce the toxicity of certain drugs; 8) the nano-emulsion has good drug dispersibility, rapid absorption, improved drug bioavailability and low viscosity; 9) the transdermal diffusion rate of the medicine can be obviously increased when the transdermal drug delivery system is used.
On the basis of the prepared nano composite, a novel hair growth promoter and an androgen receptor antagonist are sequentially added to form the composite for promoting hair growth, the small-size effect of nano particles in a nano emulsion system is utilized, active ingredients can be carried, the composite can rapidly permeate into the deep scalp layer and hair follicles, the hair follicles are activated, metabolism is promoted, the synergistic effect of the medicine and the nano emulsion is fully exerted, the effects of hair growth and hair growth are achieved, the hair loss symptom is fundamentally improved, and the healthy growth of the hair is promoted.
As a preferred embodiment of the present invention, in the nanocomposite, the mass ratio of the polyoxyethylene castor oil, lecithin, ethyl oleate, glutathione and ethanol is 15: 5: 20: 1: 10.
the invention optimizes the components of the prepared nano-composite, prepares the nano-composite according to the proportion, and obtains the composite with the particle size of about 68nm and the best stability.
Further, the nanoemulsion also comprises an auxiliary material.
As a preferable embodiment of the invention, the auxiliary material comprises a preservative accounting for 0.01-1% of the nano-emulsion by mass and/or an aromatizer accounting for 0.3-0.5% of the emulsion by mass.
As a preferred embodiment of the invention, the preservative is one or more of glyceryl caprylate, paraben, p-hydroxyacetophenone, caprylyl hydroximic acid and phenoxyethanol, and the preservative accounts for 0.1 percent of the mass of the nano emulsion; the flavoring agent is essence and accounts for 0.3% of the weight of the nano emulsion.
As a preferred embodiment of the present invention, the nano emulsion comprises the following components by mass percent: 2-10% of lecithin, 1-20% of polyoxyethylene castor oil, 5-25% of ethyl oleate, 1-5% of glutathione, 2-10% of ethanol, 5% of pyrrolidinyl diaminopyrimidine oxide, 2% of baicalin, 0.1% of phenoxyethanol, 0.3% of essence and the balance of deionized water.
The invention also provides a preparation method of the nano emulsion, which comprises the following steps:
(1) stirring polyoxyethylene castor oil, lecithin, ethyl oleate and ethanol glutathione at normal temperature, adding the balance of deionized water, uniformly mixing, and stirring to obtain a transparent and uniform nano composite;
(2) adding pyrrolidinyl diaminopyrimidine oxide and baicalin into the nano-composite in the step (1), and uniformly stirring at room temperature;
(3) and (3) adding auxiliary materials into the mixture obtained in the step (2), and uniformly stirring.
As a preferred embodiment of the invention, the stirring speed in the step (1) is 200r/min, and after adding the deionized water, the stirring is continued for 3 hours.
The invention provides a compound for promoting hair growth, which is formed by pyrrolidinyl diaminopyrimidine oxide and baicalin in a certain proportion, the pyrrolidinyl diaminopyrimidine oxide and the baicalin have a synergistic effect, and can remarkably promote hair growth and more comprehensively prevent and treat alopecia; the compound for promoting hair growth and the nano compound are prepared into corresponding nano emulsion, and a nano compound system in the nano emulsion is optimized, so that the obtained nano compound has small particle size and better stability, and can effectively assist hair growth substances to penetrate through cuticles and enter hair follicles to promote hair growth. Compared with the traditional hair restorer, the nano emulsion prepared by the invention has the advantages of safe components and no stimulation; can effectively promote hair growth and solve the problem of hair loss. The invention also provides a preparation method of the nano-composite for promoting hair growth, which has simple preparation process, can prepare the nano-composite with the hair growth effect at low temperature and normal pressure, does not adopt any toxic reagent, is green and efficient, has short period and high yield, and is easy to popularize and produce on a large scale.
Drawings
Fig. 1 shows the results of hair follicle counting by Image J software for each group of mice.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments.
Example 1
Adding 15% polyoxyethylene castor oil, 5% lecithin, 20% ethyl oleate, 10% ethanol and 1% glutathione at normal temperature and 200r/min under stirring, adding the rest of deionized water, uniformly mixing, stirring for 3h to form a transparent and uniform nano-composite, adding 5% pyrrolidinyl diaminopyrimidine oxide and 2% baicalin, stirring at room temperature, and finally adding 0.1% phenoxyethanol and 0.3% essence.
Example 2
Adding 15% of polyoxyethylene castor oil, 4% of lecithin, 25% of ethyl oleate, 2% of ethanol and 3% of glutathione into the rest of deionized water at the normal temperature and the rotation speed of 200r/min under stirring, uniformly mixing, stirring for 3h to form a transparent and uniform nano compound, adding 5% of pyrrolidinyl diaminopyrimidine oxide and 2% of baicalin, stirring at the room temperature, and finally adding 0.1% of phenoxyethanol and 0.3% of essence.
Example 3
Adding 15% polyoxyethylene castor oil, 2% lecithin, 20% ethyl oleate, 10% ethanol and 2% glutathione at normal temperature and 200r/min under stirring, adding the rest of deionized water, uniformly mixing, stirring for 3h to form a transparent and uniform nano-composite, adding 5% pyrrolidinyl diaminopyrimidine oxide and 2% baicalin, stirring at room temperature, and finally adding 0.1% phenoxyethanol and 0.3% essence.
Example 4
Adding 15% polyoxyethylene castor oil, 10% lecithin, 15% ethyl oleate, 8% ethanol and 1% glutathione into the rest of deionized water at the normal temperature of 200r/min under stirring, uniformly mixing, stirring for 3h to form a transparent and uniform nano-composite, adding 5% pyrrolidinyl diaminopyrimidine oxide and 2% baicalin, stirring at the room temperature, and finally adding 0.1% phenoxyethanol and 0.3% essence.
Example 5
Adding 20% polyoxyethylene castor oil, 6% lecithin, 10% ethyl oleate, 10% ethanol and 1% glutathione at normal temperature and 200r/min under stirring, adding the rest of deionized water, uniformly mixing, stirring for 3h to form a transparent and uniform nano-composite, adding 5% pyrrolidinyl diaminopyrimidine oxide and 2% baicalin, stirring at room temperature, and finally adding 0.1% phenoxyethanol and 0.3% essence.
Control group 1
Adding 15% polyoxyethylene castor oil, 5% lecithin, 20% ethyl oleate, 10% ethanol and 1% glutathione at normal temperature and a rotation speed of 200r/min, stirring, adding the rest of deionized water, uniformly mixing, stirring for 3h to form a transparent and uniform nano-composite, adding 3% minoxidil, stirring at room temperature, and finally adding 0.1% phenoxyethanol and 0.3% essence.
Control group 2
Adding 15% polyoxyethylene castor oil, 5% lecithin, 20% ethyl oleate, 10% ethanol and 1% glutathione at normal temperature and 200r/min under stirring, adding the rest of deionized water, uniformly mixing, stirring for 3h to form a transparent and uniform nano-composite, adding 5% pyrrolidinyl diaminopyrimidine oxide, stirring at room temperature, and finally adding 0.1% phenoxyethanol and 0.3% essence.
Control group 3
Adding 15% polyoxyethylene castor oil, 5% lecithin, 20% ethyl oleate, 10% ethanol and 1% glutathione at normal temperature and 200r/min under stirring, adding the rest of deionized water, mixing, stirring for 3 hr to obtain transparent and uniform nanometer compound, adding 2% baicalin, stirring at room temperature, and adding 0.1% phenoxyethanol and 0.3% essence.
Control group 4
Adding 15% polyoxyethylene castor oil, 5% lecithin, 20% ethyl oleate, 10% ethanol and 1% glutathione at normal temperature and 200r/min under stirring, adding the rest of deionized water, uniformly mixing, stirring for 3h to form a transparent and uniform nano-composite, adding 4% pyrrolidinyl diaminopyrimidine oxide and 3% baicalin, stirring at room temperature, and finally adding 0.1% phenoxyethanol and 0.3% essence.
Control group 5
Adding 15% polyoxyethylene castor oil, 5% lecithin, 20% ethyl oleate, 10% ethanol and 1% glutathione at normal temperature and 200r/min under stirring, adding the rest of deionized water, uniformly mixing, stirring for 3h to form a transparent and uniform nano-composite, adding 3% pyrrolidinyl diaminopyrimidine oxide and 1% baicalin, stirring at room temperature, and finally adding 0.1% phenoxyethanol and 0.3% essence.
Control group 6
Adding 15% of polyoxyethylene castor oil, 5% of lecithin, 20% of ethyl oleate, 10% of ethanol and 1% of glutathione into the rest of deionized water at the normal temperature and the rotation speed of 200r/min under stirring, uniformly mixing, stirring for 3h to form a transparent and uniform nano compound, adding 2% of pyrrolidinyl diaminopyrimidine oxide and 4% of baicalin, stirring at the room temperature, and finally adding 0.1% of phenoxyethanol and 0.3% of essence.
Blank group
Preparing nano emulsion: adding 15% polyoxyethylene castor oil, 5% lecithin, 20% ethyl oleate, 10% ethanol and 1% glutathione at normal temperature and 200r/min under stirring, adding the rest deionized water, mixing, stirring for 3 hr to obtain transparent and uniform nanometer compound, and adding 0.1% phenoxyethanol and 0.3% essence.
Optimized process for preparing nano emulsion
In order to screen out stable nano emulsion, the stable nano emulsion is obtained by optimizing the combination ratio according to 5-factor 5-level orthogonal experiment on different contents of polyoxyethylene castor oil, lecithin, ethyl oleate, glutathione and ethanol. The nanocomposite components in each test group were present in the mass percent of the total as shown in table 1.
The results are shown in table 1, when the mass fraction of the polyoxyethylene castor oil, lecithin, ethyl oleate, glutathione and ethanol is 15: 2: 20: 2: 10, the prepared nano composition has smaller grain diameter of 68nm, long stabilization time, meets the preparation requirements, and is finely adjusted on the basis that when the mass fractions of the polyoxyethylene castor oil, the lecithin, the ethyl oleate, the glutathione and the ethanol are 15: 5: 20: 1: at 10, the best effect is achieved in dissolving pyrrolidinyl diaminopyrimidine oxide and baicalin.
Table 1 five-factor five-level optimization test results
Second, safety test
The results of the skin irritation test of the hair growth promoting nanoemulsion of the present invention
Taking 35 healthy rabbits with weight of about 2kg, randomly dividing the rabbits into 7 groups, wherein each group comprises 5 rabbits, unhairing the two sides of the back skin of the rabbits 24h before the experiment, detecting whether the skin in the unhaired area is injured or not after the unhairing 24h, and applying the nano composition prepared in the examples 1-4, the control groups 1-3 and the blank groups for 3 times every day for 7 days, and observing the experiment results, wherein the experiment results are shown in table 2:
table 2 skin irritation test results
"+" indicates that the rabbit has red and swollen skin, inflammation and congestion;
"+ +" indicates that the rabbit has red and swollen skin, inflammation and congestion phenomena, and has increasing trend;
"-" indicates that the rabbit has no skin red swelling, inflammation and congestion;
as can be seen from the experimental results of table 2, the hair growth promoting nanoemulsion of the present invention has no irritation to the skin.
Second, stability test
And (3) performing centrifugal test, cold resistance test and heat resistance test on the 8 groups of nano emulsions, and primarily investigating the stability of the product.
The method comprises the following steps:
(1) and (3) centrifugal test: sampling 5g of a sample, placing the sample in a 10mL centrifugal test tube, adjusting the rotating speed to 3000r/min, centrifuging for 15min, taking out and observing;
(2) cold resistance test: weighing 10g of sample, placing the sample in a 50mL beaker, placing the beaker in a refrigerator at minus 8 ℃ for 24 hours, taking out the sample, and returning the sample to room temperature for observation;
(3) heat resistance test: 10g of the product was weighed, placed in a 50mL beaker, placed in a 55. + -. 2 ℃ desiccator for 6h and then observed.
The test results of each test are shown in Table 3.
Table 3 stability test results
From the results of table 3, it was confirmed that each sample passed the preliminary stability test without change in appearance compared to the sample before the test.
Thirdly, evaluation of the Effect of inhibiting 5 α -reductase Activity
According to related research, the 5 α -reductase catalyzes the participation of reduced coenzyme II (NADPH) required in the process of converting testosterone into dihydrotestosterone, the reduced NADPH has characteristic absorption at 340nm, the NADPH is converted into oxidized coenzyme II (NADP +) along with the reaction, the characteristic absorption at 340nm disappears, and the inhibitor effect of the 5 α -reductase can be detected according to the characteristic absorption change at 340nm of the NADPH in the reaction process.
The experimental method comprises the following steps:
(1) determination of blank control. To the reaction tube were added 2mL Buffer, 100. mu.L testosterone, 200. mu.L PBS Buffer (pH 7.2), 15. mu.L NADPH, and finally 15. mu.L enzyme, mixed and then measured for A340nm value, incubated at 37 ℃ and reacted for 10min and then measured for A340nm value. The DMSO blank reduction (. DELTA.A 0) was determined by subtracting the background of the NADPH blank reduction.
(2) And (4) measuring the inhibition effect of each group of reductase. To the reaction tube were added 2mL of Buffer (Buffer), 100. mu.L of testosterone, 200. mu.L of control group (1-4) and example group (1-4), 15. mu.L of NADPH, and finally 15. mu.L of enzyme, mixed and then measured for A340nm value, incubated at 37 ℃ and after reaction for 10min, measured for A340nm value. The reduction in reductase inhibition (. DELTA.an) was measured for each group by subtracting the background reduction in NADPH blank. The inhibition ratio of the enzyme was calculated as I (%) ═ Δ a 0- Δ An)/Δ a0 × 100%, and the experiment was repeated three times.
The results are shown in Table 4.
TABLE 4 results of experiments on inhibition of 5 α -reductase Activity
Group of | 5 α -reductase inhibition (%) |
Blank group | - |
Control group 1 | 71.6±1.5% |
Control group 2 | 58.4±1.1% |
Control group 3 | 34.7±0.6% |
Control group 4 | 68.7±1.7% |
Control group 5 | 63.5±2.1% |
Control group 6 | 58.0±0.8% |
Example 1 | 72.6±1.3% |
The experimental result in table 3 shows that the nano-composite can obviously reduce the conversion of testosterone to dihydrotestosterone, and the inhibiting effect of the compounded 5% pyrrolidinyl diaminopyrimidine oxide and 2% baicalin is improved to be close to that of the control group 1 compared with that of a single component, so that the prepared nano-composite has the activity of inhibiting 5 α -reductase.
Fourth, animal experiment
90 male mice are numbered according to weight, 10 mice are selected as blank groups according to a random number table method, and the rest mice are made into model groups. The blank group was injected with physiological saline, and the model-made mice were administered testosterone propionate subcutaneously to the back at a dose of 5mg/kg × d (0.1mg) for 6 weeks, to create an animal model of androgenetic alopecia. After the mice are successfully molded in the 6 th week of experiment, randomly dividing 80 mice of the molding group into a control group (1-4) and an example group (1-4), wherein each group comprises 10 mice, each group is externally smeared with a solution with a corresponding concentration, the external dose is 0.2ml according to the conversion of the volume of a human body/a mouse, the rest groups except a blank group are continuously injected with testosterone propionate to maintain the androgen level in the mouse, and the number of hair follicles is counted by applying Image J software to the same area of each group with the same size at the 12 th week. The results are shown in FIG. 1.
As can be seen from fig. 1, counting follicles by Image J software showed that the difference in the number of follicles was significant compared with the control group, experimental group and blank group; compared with a control group, the number of hair follicles of the experimental group is more than that of hair follicles of the control group, and the experimental result shows that the compounded pyrrolidinyl diaminopyrimidine oxide and baicalin are improved compared with that of one component used alone, and when the compounded effect of 5% of pyrrolidinyl diaminopyrimidine oxide and 2% of baicalin is the best.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention, and not for limiting the protection scope of the present invention, although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. A composition for promoting hair growth, comprising pyrrolidinyl diaminopyrimidine oxide and baicalin; the mass ratio of the pyrrolidinyl diaminopyrimidine oxide to the baicalin is 5: 2.
2. Use of a complex according to claim 1 for the preparation of a product for promoting hair growth.
3. A hair growth promoting emulsion comprising the hair growth promoting complex of claim 1 and an emulsion base.
4. The emulsion of claim 3, wherein the emulsion is a nanoemulsion and the emulsion matrix is a nanocomposite.
5. The emulsion of claim 4, wherein the nanocomposite comprises lecithin, polyoxyethylene castor oil, ethyl oleate, glutathione and ethanol, and the particle size of the nanocomposite is 10-133 nm.
6. The emulsion of claim 4, wherein the nanocomposite comprises a polyoxyethylene castor oil, lecithin, ethyl oleate, glutathione, and ethanol in a mass ratio of 15: 5: 20: 1: 10.
7. the emulsion of claim 4, further comprising an adjuvant.
8. The emulsion of claim 5, wherein the adjuvant comprises 0.01 to 1% by mass of the nanoemulsion of a preservative and/or 0.3 to 0.5% by mass of an odorant.
9. The emulsion according to claim 8, wherein the emulsion comprises the following components in percentage by mass: 5% lecithin, 15% polyoxyethylene castor oil, 20% ethyl oleate, 1% glutathione, 10% ethanol, 5% pyrrolidinyl diaminopyrimidine oxide, 2% baicalin, 0.1% phenoxyethanol, 0.3% essence and the balance of deionized water.
10. A process for the preparation of a nanoemulsion according to any of claims 4 to 9, characterised in that it comprises the following steps:
(1) stirring polyoxyethylene castor oil, lecithin, ethyl oleate and ethanol glutathione at a normal temperature and a rotating speed, adding the balance of deionized water, uniformly mixing, and stirring until a transparent and uniform nano-composite is formed;
(2) adding pyrrolidinyl diaminopyrimidine oxide and baicalin into the nano-composite in the step (1), and uniformly stirring at room temperature;
(3) and (3) adding auxiliary materials into the mixture obtained in the step (2), and uniformly stirring.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911315867.5A CN110917062A (en) | 2019-12-18 | 2019-12-18 | Nano emulsion for promoting hair growth and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911315867.5A CN110917062A (en) | 2019-12-18 | 2019-12-18 | Nano emulsion for promoting hair growth and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110917062A true CN110917062A (en) | 2020-03-27 |
Family
ID=69864338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911315867.5A Pending CN110917062A (en) | 2019-12-18 | 2019-12-18 | Nano emulsion for promoting hair growth and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110917062A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111643436A (en) * | 2020-07-16 | 2020-09-11 | 陕西中鸿科瑞再生医学研究院有限公司 | Pilatory containing sponginum spicules |
CN112569247A (en) * | 2020-12-22 | 2021-03-30 | 西华大学 | Composition for promoting hair growth and preparation method of nanoemulsion |
CN113041246A (en) * | 2021-03-22 | 2021-06-29 | 上海中医药大学 | Curcumin composition for preventing and treating alopecia |
CN114732751A (en) * | 2022-03-30 | 2022-07-12 | 彭氏(惠州)实业发展有限公司 | Anti-dropping essence containing pyrrolidinyl diaminopyrimidine oxide |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001017486A2 (en) * | 1999-09-09 | 2001-03-15 | Carlo Ghisalberti | Deanol or derivatives for the treatment of skin impairements and baldness |
KR20070030690A (en) * | 2005-09-13 | 2007-03-16 | (주)아모레퍼시픽 | Cosmetic composition containing pyrrolidinyl diaminopyrimidine oxide |
US20130017239A1 (en) * | 2010-03-24 | 2013-01-17 | Lipotec S.A. | Lipid nanoparticle capsules |
CN109528725A (en) * | 2019-01-15 | 2019-03-29 | 华中科技大学 | A kind of oxide containing di-amino-pyrimidine and the nano-composition of pyrrole alkyl amino pyrimidine oxide and the preparation method and application thereof |
US20190110969A1 (en) * | 2017-10-17 | 2019-04-18 | North Star Scientific, Inc. | Hair growth compositions and methods of use |
-
2019
- 2019-12-18 CN CN201911315867.5A patent/CN110917062A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001017486A2 (en) * | 1999-09-09 | 2001-03-15 | Carlo Ghisalberti | Deanol or derivatives for the treatment of skin impairements and baldness |
KR20070030690A (en) * | 2005-09-13 | 2007-03-16 | (주)아모레퍼시픽 | Cosmetic composition containing pyrrolidinyl diaminopyrimidine oxide |
US20130017239A1 (en) * | 2010-03-24 | 2013-01-17 | Lipotec S.A. | Lipid nanoparticle capsules |
US20190110969A1 (en) * | 2017-10-17 | 2019-04-18 | North Star Scientific, Inc. | Hair growth compositions and methods of use |
CN109528725A (en) * | 2019-01-15 | 2019-03-29 | 华中科技大学 | A kind of oxide containing di-amino-pyrimidine and the nano-composition of pyrrole alkyl amino pyrimidine oxide and the preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
邢飞: "《中药活性成分黄芩苷促进毛发生长的相关机制研究》", 《知网博士电子期刊》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111643436A (en) * | 2020-07-16 | 2020-09-11 | 陕西中鸿科瑞再生医学研究院有限公司 | Pilatory containing sponginum spicules |
CN111643436B (en) * | 2020-07-16 | 2022-03-15 | 陕西中鸿科瑞再生医学研究院有限公司 | Pilatory containing sponginum spicules |
CN112569247A (en) * | 2020-12-22 | 2021-03-30 | 西华大学 | Composition for promoting hair growth and preparation method of nanoemulsion |
CN113041246A (en) * | 2021-03-22 | 2021-06-29 | 上海中医药大学 | Curcumin composition for preventing and treating alopecia |
CN113041246B (en) * | 2021-03-22 | 2023-04-28 | 上海中医药大学 | Curcumin composition for preventing and treating alopecia |
CN114732751A (en) * | 2022-03-30 | 2022-07-12 | 彭氏(惠州)实业发展有限公司 | Anti-dropping essence containing pyrrolidinyl diaminopyrimidine oxide |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110917062A (en) | Nano emulsion for promoting hair growth and preparation method thereof | |
CA2269594C (en) | Use of complexes for the preparation of compositions for the treatment of sensitive skin, preparation process and hypoallergenic compositions | |
CN109528725B (en) | Nanometer composition containing diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide, and preparation method and application thereof | |
US8062648B2 (en) | Formulations containing melatonin, ginkgo biloba, and biotin | |
EP2885004B1 (en) | Composition comprising dihydroquercetin, alpha-tocopherol and bisabolol | |
US9839606B2 (en) | Formulation for treatment of hairs | |
CN110302091B (en) | Composition containing nicotinamide adenine dinucleotide for resisting skin aging and preparation method and application thereof | |
CN104800150A (en) | Minoxidil cream and preparation method thereof | |
KR20200028547A (en) | Transparent liposome composition containing centella asiatica extract | |
CN115778886B (en) | Glabridin plant source microcapsule inclusion and preparation method and application thereof | |
KR101841118B1 (en) | Composition for skin external application comprising extract of scenedesmus sp. | |
CN108498412B (en) | Fat-soluble glabridin compound whitening agent and application thereof | |
WO2014122436A1 (en) | Topical pharmaceutical compositions comprising minoxidil | |
CN116036196A (en) | Anti-hair loss hair-nourishing essence and preparation method thereof | |
EP4183404A1 (en) | Composition for preventing hair loss or promoting hair growth comprising extract of above-ground part of carrots | |
JP7135106B2 (en) | Scalp and hair composition | |
WO2022108913A1 (en) | Compositions and methods for deep dermal drug delivery | |
CN108653144B (en) | Whitening cosmetic | |
US20150118292A1 (en) | Compositions and methods for treatment of hair loss | |
WO2021157753A1 (en) | Composition for preventing hair loss and promoting hair regrowth | |
WO2022045261A1 (en) | Inhibitor of downregulation of cd39 gene | |
CN117731672A (en) | Preparation for promoting hair growth and preparation method and application thereof | |
US20090304613A1 (en) | Use of a limnophila extract as a cosmetic agent, and cosmetic composition containing same | |
CN116036018A (en) | Foam type hair growth liquid and preparation method thereof | |
CN114796113A (en) | Application of blumea balsamifera oil nanoemulsion in preparation of anti-tumor drugs and wound repair drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |